title: FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients.
abstract: Rituximab is a chimeric monoclonal antibody that specifically targets the CD20 surface marker expressed in neoplastic B-lymphoid cells. Combined with chemotherapy or alone, in maintenance/consolidation, it is used for the treatment of non-Hodgkin lymphoma (NHL). The role of a polymorphism in a specific Fc gamma receptor gene, FcgammaRIIa, in the clinical outcome of patients with NHL was investigated in this study. We characterized DNA samples from 64 non-Hodgkin lymphoma patients treated with rituximab using a polymerase chain reaction-restriction fragment length polymorphism method. The FcgammaRIIa HH genotype was significantly correlated with complete response to rituximab compared to the R allele (P=0.028). In terms of overall or event-free survival, no difference was found according to FcgammaRIIa alleles. We hypothesize that the HH genotype increases the affinity of the FcgammaRIIa receptor, not only for naturally occurring IgG2, but also to ameliorate connection with chimeric IgG1 rituximab, contributing to a genetic individual profile of great interest in clinical onco-hematology.
authors.affiliation: Unit of Molecular Oncology, Laboratórios piso 4, Instituto Português de Oncologia, R. Dr. Ant. Bernardino Almeida, 4200-072 Porto, Portugal.
authors.forename: Márcia
authors.initials: M
authors.lastname: Paiva
authors.forename: Herlander
authors.initials: H
authors.lastname: Marques
authors.forename: Angelo
authors.initials: A
authors.lastname: Martins
authors.forename: Paula
authors.initials: P
authors.lastname: Ferreira
authors.forename: Raquel
authors.initials: R
authors.lastname: Catarino
authors.forename: Rui
authors.initials: R
authors.lastname: Medeiros
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD / Q000235:genetics*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D005787:Gene Frequency; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D017452:Receptors, IgG / Q000235:genetics*; D000069283:Rituximab; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D000970:Antineoplastic Agents; C080568:Fc gamma receptor IIA; D017452:Receptors, IgG; D000069283:Rituximab